Clinically Meaningful Improvements in Sperm DNA Fragmentation Severity in Infertile Men Treated with Superoxide Dismutase Supplementation: A Single-Center Experience.

antioxidant male infertility semen parameters sperm DNA fragmentation superoxide dismutase

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
04 Nov 2022
Historique:
received: 11 10 2022
revised: 15 10 2022
accepted: 01 11 2022
entrez: 11 11 2022
pubmed: 12 11 2022
medline: 12 11 2022
Statut: epublish

Résumé

Background. Antioxidants are commonly used for the treatment of idiopathic male infertility. Previous studies have shown that antioxidants are able to improve sperm quality, but little is known about their impact on sperm DNA fragmentation (SDF). Preliminary findings showed that superoxide-dismutase (SOD)-based antioxidant plus hydroxytyrosol and carnosol (FertiPlus® SOD) therapy was associated with SDF improvement in a small cohort of infertile men. Therefore, we aimed to assess rates of and predictors of semen parameters and SDF improvements in infertile men treated with FertiPlus® SOD therapy (SOD+) or with other antioxidants without SOD (SOD−) in the real-life setting. Methods. Data from 60 consecutive infertile men with baseline SDF ≥ 30% and treated with SOD+ or SOD− for at least three months were analyzed. Clinical parameters and serum hormones were collected. Sperm parameters and SDF were requested at baseline and after SOD+ or SOD− treatment. Clinically meaningful SDF change after treatment was defined as SDF improvement >20% compared to baseline. Propensity score matching was performed to adjust for baseline differences between groups. Descriptive statistics were used to compare clinical and hormonal characteristics between SOD+ and SOD− groups. Semen characteristics were compared before and after treatment. Logistic regression models investigated the association between clinical variables and SDF improvement. Results. Groups were similar in terms of clinical, serum hormones and semen parameters at baseline after matching. Compared to baseline, sperm progressive motility (17 (10−36)% vs. 27 (12−41)%) and normal morphology (2 (1−6)% vs. 4 (2−6)%) significantly improved after SOD+ treatment (all p < 0.01), but not after SOD−. SDF values significantly improved after treatment in both groups, compared to the baseline evaluation (all p < 0.01). However, SDF values were lower after SOD+ than SOD− treatment (30 (22−36)% vs. 37 (31−42)%, p = 0.01). Similarly, a clinically meaningful improvement in SDF at follow-up was more frequently found after SOD+ than SOD− treatment (76.7% vs. 20.0%, p = 0.001). Multivariable logistic regression analysis showed that SOD+ treatment (OR 5.4, p < 0.001) was an independent predictor of clinically meaningful SDF improvement, after accounting for age and baseline FSH values. Conclusions. This cross-sectional study showed that, in a cohort of primary infertile men with SDF ≥ 30%, SOD-based treatment was significantly effective in improving SDF compared to antioxidants without SOD. Approximately 80% of men treated with SOD+ achieved clinically meaningful improvement in SDF after three months of treatment. Sperm progressive motility and normal morphology also improved after SOD+ therapy but not after SOD−. These results suggest that SOD+ treatment could be considered an effective option for the management of idiopathic infertile men with elevated SDF.

Identifiants

pubmed: 36362768
pii: jcm11216540
doi: 10.3390/jcm11216540
pmc: PMC9656306
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur Urol Focus. 2022 Jan;8(1):339-350
pubmed: 33422457
Methods Mol Biol. 2013;927:147-64
pubmed: 22992911
Eur Urol. 2009 Dec;56(6):1025-31
pubmed: 19297076
Eur Rev Med Pharmacol Sci. 2017 Apr;21(7):1645-1652
pubmed: 28429340
Arch Ital Urol Androl. 2017 Oct 03;89(3):212-218
pubmed: 28969406
Fertil Steril. 2020 Jun;113(6):1174-1182
pubmed: 32299615
Mol Reprod Dev. 2017 Oct;84(10):1039-1052
pubmed: 28749007
Eur Urol Focus. 2020 Jan 15;6(1):178-183
pubmed: 30082228
Fertil Steril. 2021 Jan;115(1):54-61
pubmed: 33309062
Minerva Urol Nefrol. 2018 Jun;70(3):286-299
pubmed: 29595040
Hum Reprod. 2019 Feb 1;34(2):209-217
pubmed: 30517657
Transl Androl Urol. 2017 Sep;6(Suppl 4):S695-S696
pubmed: 29082952
BJU Int. 2019 Jun;123(6):1070-1077
pubmed: 30328251
Asian J Androl. 2021 Sep-Oct;23(5):456-461
pubmed: 33835075
Hum Reprod Update. 2010 May-Jun;16(3):231-45
pubmed: 19934213
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
Asian J Androl. 2019 Sep-Oct;21(5):478-485
pubmed: 30829290
Andrology. 2020 Nov;8(6):1705-1711
pubmed: 32558292
Andrology. 2021 Nov;9(6):1843-1852
pubmed: 34169669
Andrology. 2022 Jan;10(1):128-136
pubmed: 34369670
Eur Urol. 2016 Dec;70(6):920-923
pubmed: 27343001
World J Mens Health. 2021 Apr;39(2):233-290
pubmed: 33474843
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur Urol. 2021 Nov;80(5):603-620
pubmed: 34511305
Andrology. 2022 Sep;10(6):1134-1142
pubmed: 35726049
Cochrane Database Syst Rev. 2019 Mar 14;3:CD007411
pubmed: 30866036
Asian J Androl. 2021 Sep-Oct;23(5):501-509
pubmed: 33723100
World J Mens Health. 2020 Oct;38(4):412-471
pubmed: 32777871
Andrology. 2020 May;8(3):680-687
pubmed: 31999885
Andrology. 2016 Sep;4(5):944-51
pubmed: 27368157
Int J Impot Res. 2021 Dec 1;:
pubmed: 34853436

Auteurs

Luca Boeri (L)

Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Gianpaolo Lucignani (G)

Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Letizia Maria Ippolita Jannello (LMI)

Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Matteo Turetti (M)

Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Irene Fulgheri (I)

Department of Vascular Surgery, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Carlo Silvani (C)

Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Franco Gadda (F)

Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Paola Viganò (P)

Infertility Unit, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Edgardo Somigliana (E)

Infertility Unit, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.

Emanuele Montanari (E)

Department of Urology, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.

Classifications MeSH